Platform driven collaborations Coave's ALIGATER platform enabling targeted AAV delivery across ocular and CNS indications presents a compelling opportunity for licensing or co-development agreements with biotech and pharma companies looking to improve gene therapy transduction and tissue distribution.

Differentiated capsids Recent milestones around OneAAV universal capsid, suprachoroidal capsid advantage, and a CNS targeted capsid position Coave to offer differentiated vector solutions to external programs, reducing development risk for partners.

Eye and CNS focus With a lead program targeting retinal vascular diseases and a CNS capsid showcasing portfolio breadth, Coave can partner with companies seeking to fast track ocular or CNS gene therapy programs needing efficient delivery platforms.

Global footprint A cross continental presence in Paris and Cambridge coupled with ongoing participation in major industry meetings creates multiple channels for BD engagements and joint development opportunities across EU and US markets.

Growth signals Recent financing and leadership expansion signal readiness to execute BD deals, indicating a favorable window for strategic collaborations, licensing negotiations, and sponsored research partnerships to monetize the ALIGATER platform.